Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size was valued at US$ million in 2023. With growing demand in downstream market, the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market.
As for March 26, 2020
1.BCG Vaccine Clinical Experiment for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.
The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. 'These population groups are particularly affected by the current pandemic', says Leander Grode, Managing Director of VPM 'and could therefore particularly benefit from a vaccination with VPM1002'. If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.
2.Introduce of VPM1002?a Genetically Modified More Effective BCG Vaccine
VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.
The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.
Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.
3.Research Progress for VPM1002
Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.
The vaccine is currently being tested in a further Phase III study on adult volunteers in India.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. It may include historical data, market segmentation by Type (e.g., 0.5ml Package, 1ml Package), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry. This include advancements in VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 technology, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 new entrants, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 new investment, and other innovations that are shaping the future of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. It includes factors influencing customer ' purchasing decisions, preferences for VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market.
Market Segmentation:
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market?
What factors are driving VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market opportunities vary by end market size?
How does VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 break out type, application?
According to our LPI (LP Information) latest study, the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size was valued at US$ million in 2023. With growing demand in downstream market, the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market.
As for March 26, 2020
1.BCG Vaccine Clinical Experiment for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.
The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. 'These population groups are particularly affected by the current pandemic', says Leander Grode, Managing Director of VPM 'and could therefore particularly benefit from a vaccination with VPM1002'. If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.
2.Introduce of VPM1002?a Genetically Modified More Effective BCG Vaccine
VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.
The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.
Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.
3.Research Progress for VPM1002
Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.
The vaccine is currently being tested in a further Phase III study on adult volunteers in India.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. It may include historical data, market segmentation by Type (e.g., 0.5ml Package, 1ml Package), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry. This include advancements in VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 technology, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 new entrants, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 new investment, and other innovations that are shaping the future of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. It includes factors influencing customer ' purchasing decisions, preferences for VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market.
Market Segmentation:
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- by Dosage
- 0.5ml Package
- 1ml Package
- 2ml Package
- Other
- by Type of Inoculator
- Initial Vaccinate
- Revaccination
- 0-5 Years Old
- 5-18 Years Old
- 18-45 Years Old
- 45-65 Years Old
- ?65 Years Old
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Vakzine Projekt Management (VPM)
- Serum Institute of India
What is the 10-year outlook for the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market?
What factors are driving VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market opportunities vary by end market size?
How does VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Country/Region, 2019, 2023 & 2030
2.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Segment by Type
2.2.1 0.5ml Package
2.2.2 1ml Package
2.2.3 2ml Package
2.2.4 Other
2.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type
2.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
2.3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Market Share by Type (2019-2024)
2.3.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Type (2019-2024)
2.4 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Segment by Application
2.4.1 0-5 Years Old
2.4.2 5-18 Years Old
2.4.3 18-45 Years Old
2.4.4 45-65 Years Old
2.4.5 ?65 Years Old
2.5 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application
2.5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Market Share by Application (2019-2024)
2.5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Market Share by Application (2019-2024)
2.5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Application (2019-2024)
3 GLOBAL VPM1002 (TUBERCULOSIS BCG BASED VACCINE) FOR PREVENT COVID-19 BY COMPANY
3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Breakdown Data by Company
3.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales by Company (2019-2024)
3.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Company (2019-2024)
3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Revenue by Company (2019-2024)
3.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Company (2019-2024)
3.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Company (2019-2024)
3.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Company
3.4 Key Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Location Distribution
3.4.2 Players VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR VPM1002 (TUBERCULOSIS BCG BASED VACCINE) FOR PREVENT COVID-19 BY GEOGRAPHIC REGION
4.1 World Historic VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Geographic Region (2019-2024)
4.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales by Geographic Region (2019-2024)
4.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country/Region (2019-2024)
4.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales by Country/Region (2019-2024)
4.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Revenue by Country/Region (2019-2024)
4.3 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth
4.4 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth
4.5 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth
4.6 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth
5 AMERICAS
5.1 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country
5.1.1 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024)
5.1.2 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024)
5.2 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type
5.3 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region
6.1.1 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2019-2024)
6.1.2 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2019-2024)
6.2 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type
6.3 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Country
7.1.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024)
7.1.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024)
7.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type
7.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Country
8.1.1 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024)
8.1.2 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024)
8.2 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type
8.3 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
10.3 Manufacturing Process Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
10.4 Industry Chain Structure of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Distributors
11.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Customer
12 WORLD FORECAST REVIEW FOR VPM1002 (TUBERCULOSIS BCG BASED VACCINE) FOR PREVENT COVID-19 BY GEOGRAPHIC REGION
12.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size Forecast by Region
12.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Forecast by Region (2025-2030)
12.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Forecast by Type
12.7 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Vakzine Projekt Management (VPM)
13.1.1 Vakzine Projekt Management (VPM) Company Information
13.1.2 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Portfolios and Specifications
13.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Vakzine Projekt Management (VPM) Main Business Overview
13.1.5 Vakzine Projekt Management (VPM) Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Country/Region, 2019, 2023 & 2030
2.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Segment by Type
2.2.1 0.5ml Package
2.2.2 1ml Package
2.2.3 2ml Package
2.2.4 Other
2.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type
2.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
2.3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Market Share by Type (2019-2024)
2.3.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Type (2019-2024)
2.4 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Segment by Application
2.4.1 0-5 Years Old
2.4.2 5-18 Years Old
2.4.3 18-45 Years Old
2.4.4 45-65 Years Old
2.4.5 ?65 Years Old
2.5 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application
2.5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Market Share by Application (2019-2024)
2.5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Market Share by Application (2019-2024)
2.5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Application (2019-2024)
3 GLOBAL VPM1002 (TUBERCULOSIS BCG BASED VACCINE) FOR PREVENT COVID-19 BY COMPANY
3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Breakdown Data by Company
3.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales by Company (2019-2024)
3.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Company (2019-2024)
3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Revenue by Company (2019-2024)
3.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Company (2019-2024)
3.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Company (2019-2024)
3.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Company
3.4 Key Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Location Distribution
3.4.2 Players VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR VPM1002 (TUBERCULOSIS BCG BASED VACCINE) FOR PREVENT COVID-19 BY GEOGRAPHIC REGION
4.1 World Historic VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Geographic Region (2019-2024)
4.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales by Geographic Region (2019-2024)
4.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country/Region (2019-2024)
4.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales by Country/Region (2019-2024)
4.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Revenue by Country/Region (2019-2024)
4.3 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth
4.4 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth
4.5 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth
4.6 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth
5 AMERICAS
5.1 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country
5.1.1 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024)
5.1.2 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024)
5.2 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type
5.3 Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region
6.1.1 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2019-2024)
6.1.2 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2019-2024)
6.2 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type
6.3 APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Country
7.1.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024)
7.1.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024)
7.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type
7.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Country
8.1.1 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024)
8.1.2 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024)
8.2 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type
8.3 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
10.3 Manufacturing Process Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
10.4 Industry Chain Structure of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Distributors
11.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Customer
12 WORLD FORECAST REVIEW FOR VPM1002 (TUBERCULOSIS BCG BASED VACCINE) FOR PREVENT COVID-19 BY GEOGRAPHIC REGION
12.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size Forecast by Region
12.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Forecast by Region (2025-2030)
12.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Forecast by Type
12.7 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Vakzine Projekt Management (VPM)
13.1.1 Vakzine Projekt Management (VPM) Company Information
13.1.2 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Portfolios and Specifications
13.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Vakzine Projekt Management (VPM) Main Business Overview
13.1.5 Vakzine Projekt Management (VPM) Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
.
Table 1. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of 0.5ml Package
Table 4. Major Players of 1ml Package
Table 5. Major Players of 2ml Package
Table 6. Major Players of Other
Table 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024) & (K Doses)
Table 8. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
Table 9. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2019-2024) & ($ million)
Table 10. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2019-2024)
Table 11. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Type (2019-2024) & (USD/Dose)
Table 12. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024) & (K Doses)
Table 13. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)
Table 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2019-2024)
Table 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2019-2024)
Table 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Application (2019-2024) & (USD/Dose)
Table 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Company (2019-2024) & (K Doses)
Table 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Company (2019-2024)
Table 19. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Company (2019-2024) ($ Millions)
Table 20. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Company (2019-2024)
Table 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Company (2019-2024) & (USD/Dose)
Table 22. Key Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Producing Area Distribution and Sales Area
Table 23. Players VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Products Offered
Table 24. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Geographic Region (2019-2024) & (K Doses)
Table 28. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share Geographic Region (2019-2024)
Table 29. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country/Region (2019-2024) & (K Doses)
Table 32. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country/Region (2019-2024)
Table 33. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024) & (K Doses)
Table 36. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2019-2024)
Table 37. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2019-2024)
Table 39. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024) & (K Doses)
Table 40. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024) & (K Doses)
Table 41. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2019-2024) & (K Doses)
Table 42. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2019-2024)
Table 43. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2019-2024)
Table 45. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024) & (K Doses)
Table 46. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024) & (K Doses)
Table 47. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024) & (K Doses)
Table 48. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2019-2024)
Table 49. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2019-2024)
Table 51. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024) & (K Doses)
Table 52. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024) & (K Doses)
Table 53. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024) & (K Doses)
Table 54. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024) & (K Doses)
Table 58. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024) & (K Doses)
Table 59. Key Market Drivers & Growth Opportunities of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Table 60. Key Market Challenges & Risks of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Table 61. Key Industry Trends of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Table 62. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Distributors List
Table 65. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Customer List
Table 66. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Region (2025-2030) & (K Doses)
Table 67. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Country (2025-2030) & (K Doses)
Table 69. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Region (2025-2030) & (K Doses)
Table 71. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Country (2025-2030) & (K Doses)
Table 73. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Country (2025-2030) & (K Doses)
Table 75. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Type (2025-2030) & (K Doses)
Table 77. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Application (2025-2030) & (K Doses)
Table 79. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 80. Vakzine Projekt Management (VPM) Basic Information, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturing Base, Sales Area and Its Competitors
Table 81. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Portfolios and Specifications
Table 82. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 83. Vakzine Projekt Management (VPM) Main Business
Table 84. Vakzine Projekt Management (VPM) Latest Developments
Table 85. Serum Institute of India Basic Information, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturing Base, Sales Area and Its Competitors
Table 86. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Portfolios and Specifications
Table 87. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 88. Serum Institute of India Main Business
Table 89. Serum Institute of India Latest Developments
.
Table 1. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of 0.5ml Package
Table 4. Major Players of 1ml Package
Table 5. Major Players of 2ml Package
Table 6. Major Players of Other
Table 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024) & (K Doses)
Table 8. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
Table 9. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2019-2024) & ($ million)
Table 10. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2019-2024)
Table 11. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Type (2019-2024) & (USD/Dose)
Table 12. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024) & (K Doses)
Table 13. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)
Table 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2019-2024)
Table 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2019-2024)
Table 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Application (2019-2024) & (USD/Dose)
Table 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Company (2019-2024) & (K Doses)
Table 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Company (2019-2024)
Table 19. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Company (2019-2024) ($ Millions)
Table 20. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Company (2019-2024)
Table 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sale Price by Company (2019-2024) & (USD/Dose)
Table 22. Key Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Producing Area Distribution and Sales Area
Table 23. Players VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Products Offered
Table 24. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Geographic Region (2019-2024) & (K Doses)
Table 28. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share Geographic Region (2019-2024)
Table 29. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country/Region (2019-2024) & (K Doses)
Table 32. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country/Region (2019-2024)
Table 33. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024) & (K Doses)
Table 36. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2019-2024)
Table 37. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2019-2024)
Table 39. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024) & (K Doses)
Table 40. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024) & (K Doses)
Table 41. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2019-2024) & (K Doses)
Table 42. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2019-2024)
Table 43. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2019-2024)
Table 45. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024) & (K Doses)
Table 46. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024) & (K Doses)
Table 47. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024) & (K Doses)
Table 48. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2019-2024)
Table 49. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2019-2024)
Table 51. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024) & (K Doses)
Table 52. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024) & (K Doses)
Table 53. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2019-2024) & (K Doses)
Table 54. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2019-2024) & (K Doses)
Table 58. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2019-2024) & (K Doses)
Table 59. Key Market Drivers & Growth Opportunities of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Table 60. Key Market Challenges & Risks of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Table 61. Key Industry Trends of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Table 62. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Distributors List
Table 65. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Customer List
Table 66. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Region (2025-2030) & (K Doses)
Table 67. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Country (2025-2030) & (K Doses)
Table 69. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Region (2025-2030) & (K Doses)
Table 71. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Country (2025-2030) & (K Doses)
Table 73. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Country (2025-2030) & (K Doses)
Table 75. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Type (2025-2030) & (K Doses)
Table 77. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Application (2025-2030) & (K Doses)
Table 79. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 80. Vakzine Projekt Management (VPM) Basic Information, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturing Base, Sales Area and Its Competitors
Table 81. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Portfolios and Specifications
Table 82. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 83. Vakzine Projekt Management (VPM) Main Business
Table 84. Vakzine Projekt Management (VPM) Latest Developments
Table 85. Serum Institute of India Basic Information, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturing Base, Sales Area and Its Competitors
Table 86. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Portfolios and Specifications
Table 87. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 88. Serum Institute of India Main Business
Table 89. Serum Institute of India Latest Developments
LIST OF FIGURES
.
Figure 1. Picture of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Figure 2. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth Rate 2019-2030 (K Doses)
Figure 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of 0.5ml Package
Figure 10. Product Picture of 1ml Package
Figure 11. Product Picture of 2ml Package
Figure 12. Product Picture of Other
Figure 13. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type in 2023
Figure 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2019-2024)
Figure 15. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Consumed in 0-5 Years Old
Figure 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: 0-5 Years Old (2019-2024) & (K Doses)
Figure 17. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Consumed in 5-18 Years Old
Figure 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: 5-18 Years Old (2019-2024) & (K Doses)
Figure 19. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Consumed in 18-45 Years Old
Figure 20. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: 18-45 Years Old (2019-2024) & (K Doses)
Figure 21. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Consumed in 45-65 Years Old
Figure 22. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: 45-65 Years Old (2019-2024) & (K Doses)
Figure 23. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Consumed in ?65 Years Old
Figure 24. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: ?65 Years Old (2019-2024) & (K Doses)
Figure 25. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2023)
Figure 26. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application in 2023
Figure 27. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market by Company in 2023 (K Doses)
Figure 28. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Company in 2023
Figure 29. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market by Company in 2023 ($ Million)
Figure 30. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Company in 2023
Figure 31. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Geographic Region (2019-2024)
Figure 32. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Geographic Region in 2023
Figure 33. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2019-2024 (K Doses)
Figure 34. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2019-2024 ($ Millions)
Figure 35. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2019-2024 (K Doses)
Figure 36. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2019-2024 ($ Millions)
Figure 37. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2019-2024 (K Doses)
Figure 38. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2019-2024 ($ Millions)
Figure 39. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2019-2024 (K Doses)
Figure 40. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2019-2024 ($ Millions)
Figure 41. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country in 2023
Figure 42. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country in 2023
Figure 43. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
Figure 44. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)
Figure 45. United States VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 46. Canada VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 47. Mexico VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 48. Brazil VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 49. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region in 2023
Figure 50. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Regions in 2023
Figure 51. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
Figure 52. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)
Figure 53. China VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 54. Japan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 55. South Korea VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 56. Southeast Asia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 57. India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 58. Australia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 59. China Taiwan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 60. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country in 2023
Figure 61. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country in 2023
Figure 62. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
Figure 63. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)
Figure 64. Germany VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 65. France VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 66. UK VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 67. Italy VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 68. Russia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 69. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country in 2023
Figure 70. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country in 2023
Figure 71. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
Figure 72. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)
Figure 73. Egypt VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 74. South Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 75. Israel VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 76. Turkey VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 77. GCC Country VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 78. Manufacturing Cost Structure Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 in 2023
Figure 79. Manufacturing Process Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Figure 80. Industry Chain Structure of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Figure 81. Channels of Distribution
Figure 82. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Forecast by Region (2025-2030)
Figure 83. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share Forecast by Region (2025-2030)
Figure 84. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share Forecast by Type (2025-2030)
Figure 85. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share Forecast by Type (2025-2030)
Figure 86. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share Forecast by Application (2025-2030)
Figure 87. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share Forecast by Application (2025-2030)
.
Figure 1. Picture of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Figure 2. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth Rate 2019-2030 (K Doses)
Figure 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of 0.5ml Package
Figure 10. Product Picture of 1ml Package
Figure 11. Product Picture of 2ml Package
Figure 12. Product Picture of Other
Figure 13. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type in 2023
Figure 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2019-2024)
Figure 15. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Consumed in 0-5 Years Old
Figure 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: 0-5 Years Old (2019-2024) & (K Doses)
Figure 17. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Consumed in 5-18 Years Old
Figure 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: 5-18 Years Old (2019-2024) & (K Doses)
Figure 19. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Consumed in 18-45 Years Old
Figure 20. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: 18-45 Years Old (2019-2024) & (K Doses)
Figure 21. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Consumed in 45-65 Years Old
Figure 22. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: 45-65 Years Old (2019-2024) & (K Doses)
Figure 23. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Consumed in ?65 Years Old
Figure 24. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: ?65 Years Old (2019-2024) & (K Doses)
Figure 25. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2023)
Figure 26. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application in 2023
Figure 27. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market by Company in 2023 (K Doses)
Figure 28. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Company in 2023
Figure 29. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market by Company in 2023 ($ Million)
Figure 30. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Company in 2023
Figure 31. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Geographic Region (2019-2024)
Figure 32. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Geographic Region in 2023
Figure 33. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2019-2024 (K Doses)
Figure 34. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2019-2024 ($ Millions)
Figure 35. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2019-2024 (K Doses)
Figure 36. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2019-2024 ($ Millions)
Figure 37. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2019-2024 (K Doses)
Figure 38. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2019-2024 ($ Millions)
Figure 39. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2019-2024 (K Doses)
Figure 40. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2019-2024 ($ Millions)
Figure 41. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country in 2023
Figure 42. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country in 2023
Figure 43. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
Figure 44. Americas VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)
Figure 45. United States VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 46. Canada VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 47. Mexico VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 48. Brazil VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 49. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region in 2023
Figure 50. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Regions in 2023
Figure 51. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
Figure 52. APAC VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)
Figure 53. China VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 54. Japan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 55. South Korea VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 56. Southeast Asia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 57. India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 58. Australia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 59. China Taiwan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 60. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country in 2023
Figure 61. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country in 2023
Figure 62. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
Figure 63. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)
Figure 64. Germany VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 65. France VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 66. UK VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 67. Italy VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 68. Russia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 69. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country in 2023
Figure 70. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country in 2023
Figure 71. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2019-2024)
Figure 72. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2019-2024)
Figure 73. Egypt VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 74. South Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 75. Israel VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 76. Turkey VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 77. GCC Country VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth 2019-2024 ($ Millions)
Figure 78. Manufacturing Cost Structure Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 in 2023
Figure 79. Manufacturing Process Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Figure 80. Industry Chain Structure of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Figure 81. Channels of Distribution
Figure 82. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Forecast by Region (2025-2030)
Figure 83. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share Forecast by Region (2025-2030)
Figure 84. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share Forecast by Type (2025-2030)
Figure 85. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share Forecast by Type (2025-2030)
Figure 86. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share Forecast by Application (2025-2030)
Figure 87. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share Forecast by Application (2025-2030)
More Publications
Global Pharmaceutical Starch Market Growth 2025-2031
US$ 3,660.00
May 2025
158 pages
Global Medical Overtube Market Growth 2023-2029
US$ 3,660.00
March 2023
95 pages
Global Dialysis Equipment Market Growth 2025-2031
US$ 3,660.00
May 2025
145 pages
Global Kava Extract Supplements Market Growth 2025-2031
US$ 3,660.00
December 2025
80 pages
Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
93 pages
